The following criteria for cure are recommended in the 2010 consensus statement: an IGF-1 concentration in the age-adjusted normal range and a random growth hormone concentration below 1 µg/l. If ...

Pasireotide is a promising novel treatment for acromegaly, according to the findings of a randomized phase II trial. Pasireotide is a somatostatin analog with high affinity for both somatostatin ...